SCHEMBL5544189

SCHEMBL5544189

CCCCCCN1CC(C)(C)c2cc(C)ccc21

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RARB P10826 1/20 0.45
RARG P13631 1/20 0.45
ALDH1A1 P00352 6/20 0.41
LMNA P02545 2/20 0.41
TSHR P16473 2/20 0.41
POLB P06746 1/20 0.37
EEF2K O00418 1/20 0.36
MAPT P10636 3/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
TLR8 Q9NR97 4/20 0.35
NPC1 O15118 1/20 0.33
HPGD P15428 1/20 0.33
RAB9A P51151 1/20 0.33
HSD17B10 Q99714 1/20 0.33
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
KDM4E B2RXH2 1/20 0.33
HTT P42858 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP2D6 P10635 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5542487 0.99 RARB (0.43) RARBRARGALDH1A1LMNATSHR
SCHEMBL5545905 0.94 ALDH1A1 (0.43) RARBRARGALDH1A1LMNATSHR
SCHEMBL5540500 0.88 ALDH1A1 (0.40) RARBRARGALDH1A1LMNATSHR
SCHEMBL5544184 0.84 RARB (0.44) RARBRARGALDH1A1EEF2KCYP1A2
SCHEMBL9615123 0.83 RARB (0.43) RARBRARGALDH1A1LMNAHSD17B10
SCHEMBL5542480 0.83 RARB (0.42) RARBRARGALDH1A1LMNATSHR
SCHEMBL5542437 0.82 ALDH1A1 (0.39) ALDH1A1LMNATSHRPOLBMAPT
SCHEMBL9079557 0.81 NOTUM (0.46) RARBRARGALDH1A1LMNAEEF2K
SCHEMBL30928324 0.81 NOTUM (0.46) RARBRARGALDH1A1LMNAEEF2K
SCHEMBL10331082 0.81 NOTUM (0.46) RARBRARGALDH1A1LMNAEEF2K

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 RARB 59/4885RARG 155/4885ALDH1A1 355/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.